Bristol-Myers Squibb (BMY) Reiterated at Neutral by Cantor Fitzgerald on Eliquis Outlook
Tweet Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $54.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
